PMID- 28176892
OWN - NLM
STAT- MEDLINE
DCOM- 20171010
LR  - 20181202
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 12
DP  - 2017
TI  - Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic 
      obstructive pulmonary disease: a network meta-analysis.
PG  - 367-381
LID - 10.2147/COPD.S119908 [doi]
AB  - PURPOSE: Long-acting beta2-agonists (LABAs) have demonstrated efficacy in patients 
      with COPD in clinical trials. The purpose of this study was to assess the 
      comparative efficacy of all available dosages of all LABA monotherapies using a 
      network meta-analysis. METHODS: A systematic literature review identified 33 
      randomized controlled trials of LABA monotherapies (salmeterol 50 mug twice daily 
      [BID]; formoterol 12 mug BID; indacaterol 75, 150, and 300 mug once daily [OD]; 
      olodaterol 5 and 10 mug OD, and vilanterol 25 mug OD). Clinical efficacy was 
      evaluated at 12 and 24 weeks in terms of trough forced expiratory volume in 1 
      second (FEV(1)), transition dyspnea index focal score, St George's Respiratory 
      Questionnaire total score, and rate of COPD exacerbations. The relative 
      effectiveness of all LABA monotherapies was estimated by Bayesian network 
      meta-analysis. RESULTS: At 12 and 24 weeks, indacaterol 300 and 150 mug OD were 
      associated with statistically significant improvement in trough FEV(1) compared 
      to all other LABA monotherapies; vilanterol 25 mug OD was superior to formoterol 
      12 mug BID. At 12 weeks, indacaterol 75 mug OD was associated with significant 
      improvement in trough FEV(1) compared to formoterol 12 mug BID and olodaterol (5 
      and 10 mug OD); salmeterol 50 mug BID was superior to formoterol 12 mug BID and 
      olodaterol 5 mug OD. Indacaterol 300 mug OD was also associated with significant 
      improvement in transition dyspnea index focal score compared to all other LABAs 
      at 12 or 24 weeks. Indacaterol 150 mug OD had significantly better results in 
      exacerbation rates than olodaterol 5 mug and olodaterol 10 mug OD. CONCLUSION: 
      Indacaterol 300 mug, followed by 150 and 75 mug, were the most effective LABA 
      monotherapies for moderate to severe COPD.
FAU - Donohue, James F
AU  - Donohue JF
AD  - Department of Pulmonary Diseases and Critical Care Medicine, The University of 
      North Carolina, Chapel Hill, NC.
FAU - Betts, Keith A
AU  - Betts KA
AD  - Analysis Group, Inc., Los Angeles, CA.
FAU - Du, Ella Xiaoyan
AU  - Du EX
AD  - Analysis Group, Inc., Los Angeles, CA.
FAU - Altman, Pablo
AU  - Altman P
AD  - Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
FAU - Goyal, Pankaj
AU  - Goyal P
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Keininger, Dorothy L
AU  - Keininger DL
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Gruenberger, Jean-Bernard
AU  - Gruenberger JB
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Signorovitch, James E
AU  - Signorovitch JE
AD  - Analysis Group, Inc., Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20170119
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Bronchodilator Agents)
SB  - IM
MH  - Adrenergic beta-2 Receptor Agonists/*administration & dosage/adverse effects
MH  - Bayes Theorem
MH  - Bronchodilator Agents/*administration & dosage/adverse effects
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Evidence-Based Medicine
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Lung/*drug effects/physiopathology
MH  - Network Meta-Analysis
MH  - Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology
MH  - Randomized Controlled Trials as Topic
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC5261557
OTO - NOTNLM
OT  - COPD
OT  - indacaterol
OT  - long-acting beta2-agonists
OT  - network meta-analysis
OT  - systematic literature review
COIS- J-BG, PG, PA, and DLK are employees of Novartis and own stock/stock options. KAB, 
      EXD, and JES are employees of Analysis Group Inc., which has received consultancy 
      fees from Novartis. JFD is a member of the Data Safety Monitoring Board for 
      Novartis, AstraZeneca, Gilead, CSA Medical, and Insmed, and is a consultant to 
      AstraZeneca, Sunovion, and GlaxoSmithKline. The authors report no other conflicts 
      of interest in this work.
EDAT- 2017/02/09 06:00
MHDA- 2017/10/11 06:00
PMCR- 2017/01/19
CRDT- 2017/02/09 06:00
PHST- 2017/02/09 06:00 [entrez]
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
PHST- 2017/01/19 00:00 [pmc-release]
AID - copd-12-367 [pii]
AID - 10.2147/COPD.S119908 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:367-381. doi: 
      10.2147/COPD.S119908. eCollection 2017.